AR and prostate carcinoma: Advanced techniques such as chromatin immunoprecipitation sequencing (ChIP-Seq) have been used to identify genome-wide AR-binding on AREs in androgen-insensitive prostate cancer cell lines [106] and in the mouse epididymis [107].